287 related articles for article (PubMed ID: 31481034)
1. Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life.
Yi QT; Gong M; Chen CH; Hu W; Zhu RJ
BMC Urol; 2019 Sep; 19(1):82. PubMed ID: 31481034
[TBL] [Abstract][Full Text] [Related]
2. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
[TBL] [Abstract][Full Text] [Related]
3. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction.
Masumori N; Tsukamoto T; Yanase M; Horita H; Aoki M
Adv Urol; 2010; 2010():205251. PubMed ID: 20981257
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
Tsujimura A; Takao T; Uchida K; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Hirai T; Kiuchi H; Miyagawa Y; Takahashi T; Kojimaan Y; Okuyama A
Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):686-92. PubMed ID: 19999133
[TBL] [Abstract][Full Text] [Related]
8. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
9. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
[TBL] [Abstract][Full Text] [Related]
10. The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS.
Tsai CH; Lee WC; Shen YC; Wang HJ; Chuang YC
Int Urol Nephrol; 2020 May; 52(5):815-820. PubMed ID: 31897874
[TBL] [Abstract][Full Text] [Related]
11. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.
Lee KS; Yoo TK; Liao L; Wang J; Chuang YC; Liu SP; Chu R; Sumarsono B
BMC Urol; 2017 Nov; 17(1):108. PubMed ID: 29162085
[TBL] [Abstract][Full Text] [Related]
12. Treatment of overactive bladder in men: Is it really different?
Shapiro KK; Brucker BM
Neurourol Urodyn; 2022 Nov; 41(8):1975-1982. PubMed ID: 35781322
[TBL] [Abstract][Full Text] [Related]
13. Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.
Yoo S; Oh S; Kim HS; Choi HS; Park J; Cho SY; Son H; Jeong H; Lee HW; Cho MC
BJU Int; 2018 Oct; 122(4):667-672. PubMed ID: 29745000
[TBL] [Abstract][Full Text] [Related]
14. What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
Matsukawa Y; Majima T; Takai S; Funahashi Y; Kato M; Gotoh M
Urol Int; 2019; 103(4):439-443. PubMed ID: 31554005
[TBL] [Abstract][Full Text] [Related]
15. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
16. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
Cornu JN; Grise P
Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
[TBL] [Abstract][Full Text] [Related]
17. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Wang YY; Shi GW; He JY; Zhang YB
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
[TBL] [Abstract][Full Text] [Related]
18. [Urinary prostaglandins E2 correlates to overactive bladder symptoms in patients with benign prostatic hyperplasia].
Zhang YJ; Bai Q
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):244-8. PubMed ID: 24738462
[TBL] [Abstract][Full Text] [Related]
19. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
